Rexahn Pharmaceuticals, Inc. (NYSE:RNN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “

Separately, FBR & Co reiterated an “outperform” rating and set a $3.00 target price on shares of Rexahn Pharmaceuticals in a research report on Wednesday, October 5th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.2051 on Wednesday. The firm’s market capitalization is $43.75 million. Rexahn Pharmaceuticals has a 12 month low of $0.20 and a 12 month high of $0.52. The company has a 50-day moving average price of $0.23 and a 200-day moving average price of $0.27.

Rexahn Pharmaceuticals (NYSE:RNN) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. Equities analysts forecast that Rexahn Pharmaceuticals will post ($0.07) EPS for the current fiscal year.

An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. increased its position in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned approximately 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent quarter.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

5 Day Chart for NYSE:RNN

Get a free copy of the Zacks research report on Rexahn Pharmaceuticals (RNN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.